A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease who Failed Prior Biologic Treatment @ Long Island Clinical Research Associates
Brief description of study
The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2. The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.
Clinical Study Identifier: s17-00761
ClinicalTrials.gov Identifier: NCT03104413
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
